Fig. 1: Baseline genetic and tumour immune microenvironment characteristics.

a Part 1 (all-comer ovarian and endometrial cancer dose-finding phase). b Part 2 (dose expansion). Patients in panels a and b are sorted from left to right by greatest reduction in SLD of target lesions. Tumour and biomarker characteristics are described according to the result from central review. However, patients could be enrolled or assigned to a cohort on the basis of local test results, to avoid delays in treatment initiation. In some cases, this resulted in a patient apparently being ineligible for the cohort in which they were treated. ^*BRCA1 mutation (p.D120H) with unknown functional consequence. ^†Patients who had NA/ND status for both BRCA mutation and LOH were enrolled based on local testing results. ^§Patient achieved CR despite best SLD change of –67% because the primary lesion (lymph node) decreased to <10 mm. CC clear-cell, CR complete response, EC endometrial cancer, HGS high-grade serous, HGS/C high-grade serous/carcinosarcoma, IC immune cell, LOH loss of heterozygosity, MSI, microsatellite instability, MSS microsatellite stable, NA not available, ND not done, OC ovarian cancer, PD progressive disease, PD-L1 programmed cell death-ligand 1, PFS progression-free survival, PP primary peritoneal cancer, PR partial response, RECIST Response Evaluation Criteria in Solid Tumours, SD stable disease, SLD sum of longest diameters, TMB tumour mutational burden, TNBC triple-negative breast cancer.